Synex Biotech Profile
Key Indicators
- Authorised Capital ₹ 4.53 Cr
as on 16-11-2024
- Paid Up Capital ₹ 4.52 Cr
as on 16-11-2024
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 15.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 8.00 Cr
as on 16-11-2024
- Revenue -4.42%
(FY 2023)
- Profit -111.70%
(FY 2023)
- Ebitda -208.13%
(FY 2023)
- Net Worth -192.82%
(FY 2023)
- Total Assets -0.92%
(FY 2023)
About Synex Biotech
The Corporate was formerly known as Pozzolana Concrete Products Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.53 Cr and a paid-up capital of Rs 4.52 Cr.
The company currently has active open charges totaling ₹15.00 Cr. The company has closed loans amounting to ₹8.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sunil Saboo, Rudraksh Somani, and Sripriya Palod serve as directors at the Company.
- CIN/LLPIN
U26950MP2011PTC026692
- Company No.
026692
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Sep 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Dhar, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Synex Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Saboo  | Director | 25-Jul-2017 | Current |
| Rudraksh Somani | Director | 01-Jul-2017 | Current |
| Sripriya Palod | Director | 19-Jun-2024 | Current |
Financial Performance of Synex Biotech.
Synex Biotech Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.42% decrease. The company also saw a substantial fall in profitability, with a 111.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 192.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synex Biotech?
In 2023, Synex Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of India Creation Date: 10 Oct 2019 | ₹15.00 Cr | Open |
Others Creation Date: 18 Sep 2018 | ₹8.00 Cr | Satisfied |
How Many Employees Work at Synex Biotech?
Unlock and access historical data on people associated with Synex Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Synex Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synex Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
